References
Leape LL, Brennan TA, Laird N, et al.: The nature of adverse events in hospitalized patients: results of the Harvard Medical Practice Study II. N Engl J Med 1991, 324:377–384.
Leape LL: Preventing adverse drug events. Am J Health Syst Pharm 1995, 52:379–382.
Anderson BJ, Ellis JF: Common errors of drug administration in infants: causes and avoidance. Paediatr Drugs 1999, 1:93–107.
Taxis K, Barber N: Ethnographic study of incidence and severity of intravenous drug errors. BMJ 2003, 326:684–687.
Bordun LA, Butt W: Drug errors in intensive care. J Paediatr Child Health 1992, 28:309–311.
Gurney H: How to calculate the dose of chemotherapy. Br J Cancer 2002, 86:1297–1302.
Gurney HP, Ackland S, Gebski V, et al.: Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation. J Clin Oncol 1998, 16:2299–2304.
de Jong FA, Mathijssen RHJ, Xie R, et al.: Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability. Clin Cancer Res 2004, 10:4068–4071.
Miller AA, Rosner GL, Egorin MJ, et al.: Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics/ pharmacodynamics in women with solid tumors (CALGB 9763) [abstract]. Proc ASCO 2003, 22:125a.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Markman, M. ‘Flat-fixed dosing’ of chemotherapy: A concept whose time has come?. Curr Oncol Rep 7, 1–2 (2005). https://doi.org/10.1007/s11912-005-0014-0
Issue Date:
DOI: https://doi.org/10.1007/s11912-005-0014-0